We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Integumen Plc | LSE:SKIN | London | Ordinary Share | GB00BMGWZY29 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 28.00 | 28.00 | 29.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMSKIN
RNS Number : 5677X
Integumen PLC
30 April 2019
30 April 2019
Integumen PLC
("Integumen" or "Company")
Result of General Meeting
At a general meeting held earlier today, all the Resolutions were passed and the Proposals (as set out in the announcement of 12 April 2019) have completed. It is expected that the 476,722,882 New Ordinary Shares, the subject of the Proposals, will be allotted later today, and Admission is expected to take place on Thursday 2 May 2019.
Enquiries:
Hot Features
Premium
+44 (0) 7340 055
Integumen plc Gerard Brandon, CEO 643
SPARK Advisory Partners
Limited Neil Baldwin/Vassil
(Nominated Adviser) Kirtchev +44 (0) 113 370 8974
Turner Pope Investments
(TPI) Limited
(Broker) Andy Thacker +44 (0) 20 3621 4120
About Integumen
Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.
The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.
Definitions used in this announcement are the same as those in the announcement of 12 April 2019.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
ROMEANLEDSKNEEF
(END) Dow Jones Newswires
April 30, 2019 08:18 ET (12:18 GMT)
1 Year Integumen Chart |
1 Month Integumen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
